|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1455 PENNSYLVANIA AVENUE NW |
Address2 | SUITE 500 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Bridgewater |
State | NJ |
Zip Code | 08807 |
Country | USA |
|
5. Senate ID# 56838-12
|
||||||||
|
6. House ID# 351860000
|
||||||||
| TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Patrick McLain |
Date | 10/14/2015 2:15:34 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; issues related to the Over The Counter (OTC) Monograph reform; general issues related to access to adult vaccines; and all provisions of S1972 "Airline Access to Emergency Epinephrine Act of 2015.".
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alison |
Bonebrake |
|
|
|
Sean |
Callinicos |
|
|
|
MaryAnne |
Dunlap |
|
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; issues related to the veterinary biologics National Environmental Policy Act (NEPA) exclusion; and all provisions of HR3174 and S1200 "Fairness to Pet Owners Act of 2015."
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Patrick |
McLain |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ECN
16. Specific lobbying issues
General issues related to the importance of foreign direct investment in the U.S.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
McLain |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi SA, the foreign parent corporation of Sanofi US Services Inc. invests in its business in the U.S.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; and general issues related to chronic care reform in the Medicare program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
|
Sean |
Callinicos |
|
|
|
Alison |
Bonebrake |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
MaryAnne |
Dunlap |
|
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
General issues related to the 340B Federal Drug Pricing Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alison |
Bonebrake |
|
|
|
Patrick |
McLain |
|
|
|
MaryAnne |
Dunlap |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
|
MaryAnne |
Dunlap |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
| Sanofi Pasteur |
|
|
||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |